Autism Spectrum Disorder Therapeutics Market, by Drug Type, by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

Global Autism Spectrum Disorder Therapeutics Market, By Age Group:

Child

Adult

Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Autism Spectrum Disorder Therapeutics Market, By Region:

North America

By Country:

U.S.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Canada

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Germany

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Italy

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Spain

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

France

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Russia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Europe

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

China

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Japan

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

India

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

ASEAN

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Australia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

South Korea

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Asia Pacific

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Mexico

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Argentina

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Latin America

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Israel

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Middle East

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country/Region:

South Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Central Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

F. Hoffmann-La Roche AG.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Neurim Pharmaceuticals, Inc.

Yamo Pharmaceuticals LLC

Servier Laboratories Ltd.

Otsuka Holdings Co. Ltd.

Curemark LLC

Oryzon Genomics S.A.

GW Pharmaceuticals Plc.

Teva Pharmaceutical Industries Ltd.

Zynerba Pharmaceuticals Inc.

Stalicla SA.

Novartis AG

Pfizer, Inc.

Bristol Myers Squibb.

"*" marked represents similar segmentation in other categories in the respective section.